geneMAP™ BCR-ABL1 P210 (Mbcr) IS-MMR Detection Kit (BCR210-RT48)
- Superior Analytical Sensitivity (Log5 Reduction)
- International Scale (IS) Results
- Fast and Easy to Use with One Step RT-qPCR Technology
- Accurate Relative Quantitation with Multiplex PCR (BCR-ABL1/ABL1)
- Compatible with FAM and VIC/HEX Dual Color Real-Time PCR Instruments
Chronic myeloid leukemia (CML) is a slowly-progressing cancer characterized by the clonal myeloproliferative expansion of pluripotent hematopoietic stem cells resulting from acquisition of the fusion oncogene BCR-ABL1. Primarily occurring in adults, CML can change into a fast-growing and difficult to treat disease. Chronic myeloid leukemia accounts for 15% of all leukemias in adults
BCR-ABL1 refers to the fusion gene which results from a reciprocal translocation that joins the ABL1 gene from chromosome 9 to the BCR gene on chromosome 22, and is necessary for the development of CML. This reciprocal translocation also generates a shortened derivative chromosome 22, known as the Philadelphia (Ph) chromosome The Ph chromosome is a diagnostic hallmark, present in 95% of people with CML and approximately 3%–5% children and 25%– 40% adults with ALL
Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients requires integration of clinical and laboratory monitoring. Assessment of molecular response (MR) by real-time quantitative polymerase chain reaction is the most sensitive way to monitor tyrosine kinase inhibitor (TKI) treatment efficacy. Besides major molecular response, which has emerged as a safe haven for survival since the initial studies of first-line imatinib treatment, two additional MR milestones have recently been defined: early molecular response and deep molecular response. The achievement of such MR milestones within defined time points during therapy is thought to draw the ideal trajectory toward optimal long-term outcome and, possibly, successful treatment discontinuation. Sensitive and reproducible MR measurement and proper interpretation of MR results are therefore critical to correctly inform therapeutic decisions.
The geneMAP™ BCR-ABL1 p210 IS-MMR assay yields results on the International Scale (International Scale-IS) for monitoring both early molecular response and deep molecular response in monitoring tyrosine kinase inhibitor treatment efficacy in CML disease. With its one-step multiplex technology and sensitivity, it is far ahead of its competitors.